Mexico and Brazil do not plan to restrict access to AstraZeneca’s COVID-19 vaccine after the UK’s drug regulator recommended it amid a potential risk for blood clots.
The statements come to the UK Regulatory Agency (MHRA) recommended that the vaccine can only be used in people older than 30 because of the possible link with rare blood clots.
The agency said it had reviewed 79 reports of rare blood clots following the administration of the vaccine, with 19 deaths. Eleven of the 19 who died were under the age of 50, while three were under the age of 30.
Cofepris, Mexico’s drug regulator, said it was still reviewing the recommendations. However, it does not plan to restrict the use of AstraZeneca vaccines to any age or group, “Reuters said. report. Mexico has so far obtained 3.5 million doses of the vaccine.
Meanwhile, Brazilian health regulator Anvisa said the benefits of the vaccine outweighed the risks, and recommended its use. The news office noted that Brazil had administered more than 4 million shots of the vaccine, and that only 47 coagulation events had been registered.
The British recommendation came on the same day that the Security Panel of the European Medicines Agency (EMA) concluded that apossible linkBetween rare blood clots and the vaccine exists.
Concerns about blood clots in a small number of patients have led to more than a dozen countries suspending the use of the vaccine last month. Oxford University a clinical trial stopped to test the vaccine in 300 children aged 6 to 17 years while awaiting the MHRA’s opinion on the reports of blood clotting.
AstraZeneca claims that the evidence did not find a causal link between the vaccine and blood clotting.